The role of neuronal nicotinic acetylcholine receptors in antinociception: Effects of ABT-594

Journal of Physiology Paris

Volumn 92, Issue 3-4, 1998, Pages 221-224

  Decker, Michael W ^a   Curzon, Peter ^a   Holladay, Mark W ^a   Nikkel, Arthur L ^a   Bitner, R Scott ^a   Bannon, Anthony W ^a   Donnelly Roberts, Diana L ^a   Puttfarcken, Pamela S ^a   Kuntzweiler, Theresa A ^a   Briggs, Clark A ^a   Williams, Michael ^a   Arneric, Stephen P ^a  

^a Pharmaceutical Products Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; LIDOCAINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROPATHY; NONHUMAN; PAIN THRESHOLD; RAPHE MAGNUS NUCLEUS; RAT; SEROTONINERGIC NERVE CELL;

EID: 0032105335     PISSN: 09284257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4257(98)80014-4     Document Type: Conference Paper

References (17)

1. [1] Aceto M.D., Awaya H., Martin B.R. May E.L., Antinociceptive action of nicotine and its methiodide derivatives in mice and rats, Br. J. Pharmacol. 79 (1983) 869-876.
2. [2] Badio B. Daly J.W., Epibatidine, a potent analgetic and nicotinic agonist, Mol. Pharmacol. 45 (1994) 563-569.
3. [3] Bannon A.W., Decker M.W., Curzon P., Buckley M.J., Kim D.J.B., Radek R.J., Lynch J.K., Wasicak J.T., Arnold W.H., Holladay M.W., Arneric S.P., ABT-594 [5-((2R)-azetidinyl-methoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors. II. In vivo characterization, J. Pharmacol. Exp. Ther. 285 (1998), 787-794.
4. [4] Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M. Arneric S.P., Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors, Science 279 (1998) 77-81.
5. [5] Bitner R.S., Nikkel A.L., Curzon P., Arneric S.P., Bannon A.W., Decker M.W., Role of the nucleus raphe magnus in antinociception produced by ABT-594: Immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons, J. Neurosci. 18 (1998) 5426-5432.
6. [6] Decker M.W., Bannon A.W., Buckley M.J., Kim D.J.B., Holladay M.W., Ryther K.B., Lin N.-H., Wasicak J.T., Williams M. Arneric S.P., Antinociceptive effects of the novel neuronal nicotinic acetylycholine receptor agonist, ABT-594, in mice, Eur. J. Pharmacol. 346 (1998) 23-33.
7. [7] Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Manelli A., Piatonni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P., ABT-594((R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine): I. In vitro profile of a novel analgesic neuronal acetylcholine (nAChR) ligand, JJ, Pharmacol. Exp. Ther. 285 (1998) 777-786.
8. [8] Fields H.L., Heinricher M.M. Mason P., Neurotransmitters in nociceptive modulatory circuits, Annu. Rev. Neuroscience 14 (1991) 219-245.
9. [9] Holladay M.W., Dart M.J. Lynch J.K., Neuronal nicotinic acetylcholine receptors as targets for drug discovery, J. Med. Chem. 40 (1997) 4169-4194.
10. [10] Holladay M.W., Wasicak J.T., Lin N.H., He Y., Ryther K.B., Bannon A.W., Buckley M.J., Kim D.J.B., Decker M.W., Anderson D.J., Campbell J.E., Kuntzweiler T.A., Donnelly-Roberts D.L., Piattoni-Kaplan M., Briggs C.A., Williams M. Arneric S.P., Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors, J. Med. Chem. 41 (1998) 407-412.
11. [11] Iwamoto E.T., Antinociception after nicotine administration into the mesopontine tegmentum of rats: Evidence for muscarinic actions, J. Pharmacol. Exp. Ther. 251 (1989) 412-421.
12. [12] Iwamoto E.T., Characterization of the aninociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus, J. Pharmacol. Exp. Ther. 257 (1990) 120-133.
13. [13] Ribeiro E.B., Bettiker R.L., Bogdanov M. Wurtman R.J., Effects of systemic nicotine on serotonin release in rat brain, Brain Res. 621 (1993) 311-318.
14. [14] Rogers D. T. Iwamoto E.T., Multiple spinal mediators in parenteral nicotine-induced antinociception, J. Pharmacol. Exp. Ther. 267 (1993) 341-349.
15. [15] Sullivan J.P., Briggs C.A., Donnelly-Roberts D., Brioni J.D., Radek R.J., McKenna D.G., Campbell J.E., Arneric S.P., Decker M.W., Bannon A.W., (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs), Med. Chem. Res. 4 (1994) 502-516.
16. [16] Sullivan J.P., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C., Adams P., Piattoni-Kaplan M., Buckley M.J., Gopalakrishnan M., Williams M. Arneric S.P., (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors, J. Pharmacol. Exp. Ther. 271 (1994) 624-631.
17. [17] Tripathi H.L., Martin B.R. Aceto M.D., Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels, J. Pharmacol. Exp. Ther. 221 (1982) 91-96.